title: Is fibromyalgia an endocrine/endorphin deficit disorder? Is low dose naltrexone a new treatment option?
authors.affiliation: Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY 13210, USA. ramanats@upstate.edu
authors.forename: Seethalakshmi
authors.initials: S
authors.lastname: Ramanathan
authors.forename: Jaak
authors.initials: J
authors.lastname: Panksepp
authors.forename: Brian
authors.initials: B
authors.lastname: Johnson
mesh_terms: D000328:Adult; D004723:Endorphins / Q000172:deficiency / Q000187:drug effects; D005260:Female; D005356:Fibromyalgia / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008297:Male; D009271:Naltrexone / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D009292:Narcotic Antagonists / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D010147:Pain Measurement / Q000379:methods; D017288:Pain Threshold / Q000187:drug effects; D011788:Quality of Life; D016896:Treatment Outcome
chemical_list: D004723:Endorphins; D009292:Narcotic Antagonists; D009271:Naltrexone